RNA interference subsidiary in S-1 filing

November 12, 2007 | Analyst Insight

CytRx recently announced that it had filed an S-1 with the Securities and Exchange Commission (SEC) for its majority-owned subsidiary RXi Pharmaceuticals for a public offering. RXi is focused on...